Compounded Tirzepatide vs Mounjaro: Real Differences
Introduction
Mounjaro® is Eli Lilly’s brand-name tirzepatide, FDA-approved in May 2022 for type 2 diabetes. Compounded tirzepatide is the same drug substance prepared by a licensed pharmacy at custom doses, sold cash-pay through telehealth platforms. The molecule is identical. Almost everything else differs.
This breakdown covers the seven differences that change cost, access, and risk: pricing, dosing format, FDA approval status, ingredient lists, supply chain, clinical evidence, and the October 2024 FDA shortage decision that changed the legal landscape.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
What’s the Molecular Difference Between the Two?
There isn’t one at the active drug level. Both products contain tirzepatide, a dual GIP and GLP-1 receptor agonist with a 5-day half-life. Eli Lilly synthesized and patented tirzepatide, then ran the SURPASS program for type 2 diabetes and the SURMOUNT program for obesity.
Quick Answer: Mounjaro and compounded tirzepatide use the same dual GIP/GLP-1 receptor agonist, tirzepatide
Compounded tirzepatide uses API sourced from registered manufacturers. The pharmacy reconstitutes the powder into an injectable solution with bacteriostatic water or sterile saline. As with semaglutide, salt form matters: tirzepatide base mirrors the brand product, while certain salt forms (acetate, sodium) have been flagged by the FDA as not equivalent to the approved ingredient.
If your compounded tirzepatide is the base form from a licensed US pharmacy with batch testing, the molecule is the same as Mounjaro.
How Does the Cost Compare?
Mounjaro’s US list price is $1,069.08 per month. With commercial insurance and the Eli Lilly savings card, eligible diabetes patients can pay $25 monthly. Cash patients without coverage paid close to retail until Eli Lilly launched LillyDirect, which offers Zepbound® (the obesity-indicated tirzepatide twin) at $349 to $499 monthly through self-pay.
Compounded tirzepatide ran $279 to $599 monthly across major US telehealth platforms in 2024-2025, depending on dose. Lower doses cost less; higher doses cost more.
Annual cost: Mounjaro at retail without coverage is around $12,800; compounded runs $3,300 to $7,200 annually. With insurance covering Mounjaro at a low copay, brand wins. Cash-pay, compounded wins on price, with the caveat that Eli Lilly’s direct vials have narrowed the gap.
Why Is Mounjaro FDA-approved but Compounded Isn’t?
Mounjaro was approved May 2022 via NDA 215866 for type 2 diabetes, backed by SURPASS-1 through SURPASS-5. The FDA reviewed manufacturing, efficacy, and safety. Eli Lilly maintains post-market surveillance through MedWatch.
Compounded drugs are legal under sections 503A and 503B of the FDCA but don’t carry FDA approval of the finished product. The legality of compounded tirzepatide hinges on whether the pharmacy meets the requirements of 503A (patient-specific) or 503B (outsourcing facility) and whether the active ingredient meets bulk drug substance criteria.
This doesn’t mean compounded is dangerous by default. It means oversight differs.
How Do the Dosing Formats Differ?
Mounjaro and Zepbound ship in single-use autoinjectors at six fixed doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. You press the device against your skin. The dose is metered.
Compounded tirzepatide ships in multi-dose vials. Your provider writes a prescription in milligrams. You draw the dose into a U-100 syringe each week. The flexibility is real: a patient who can’t tolerate jumping from 5 to 7.5 mg might hold at 6 mg or 6.5 mg, doses Mounjaro doesn’t offer. The downside is user error in drawing the right unit count.
SURMOUNT-1 (Jastreboff et al. 2022 NEJM) titrated tirzepatide to 5, 10, or 15 mg weekly across 72 weeks. That’s the dose framework most compounded protocols follow.
What’s in the Formulation Besides Tirzepatide?
Mounjaro’s inactive ingredients are sodium chloride, sodium phosphate dibasic heptahydrate, and water for injection. Nothing else.
Compounded tirzepatide often adds B12 (cyanocobalamin), B6, or in some cases niacinamide. Vendors pitch these as side-effect reducers or energy aids. There’s no randomized trial evidence that B12 in injectable tirzepatide improves outcomes or tolerability. The FDA has specifically warned about adding ingredients to compounded GLP-1 and GIP/GLP-1 products because each addition changes the stability and sterility profile.
Some compounded formulas use different preservatives or buffer systems. If you’re allergic to any inactive ingredient, ask for the full formulation sheet before injecting.
Key Takeaway: The FDA ruled tirzepatide was no longer in shortage in October 2024, closing the 503B compounding lane
What Does the Clinical Trial Data Show for Each?
Mounjaro has the SURPASS trial program (1 through 5) showing A1c reductions of 1.87% to 2.59% and weight loss up to 12.9 kg at 15 mg over 40-52 weeks. SURPASS-2 (Frias et al. 2021 NEJM) compared tirzepatide directly to semaglutide 1 mg in type 2 diabetes, showing tirzepatide superiority on A1c and weight loss. The obesity-indicated twin, Zepbound, has SURMOUNT-1 (20.9% weight loss at 72 weeks on 15 mg in adults without diabetes), SURMOUNT-2 (in type 2 diabetes), SURMOUNT-3, SURMOUNT-4, and SURMOUNT-OSA (FDA-approved for OSA in December 2024).
Compounded tirzepatide has zero randomized trials. Vendors lean on the SURPASS and SURMOUNT data, on the assumption that the same molecule produces the same effect. That’s a defensible assumption if pharmacy quality holds.
What Changed with the October 2024 Shortage Decision?
The FDA declared tirzepatide in shortage in December 2022. From late 2022 to October 2024, 503B outsourcing facilities legally compounded copies of Mounjaro and Zepbound. The market grew fast.
In October 2024, the FDA ruled tirzepatide was no longer in shortage. A federal court initially blocked enforcement after a compounding industry lawsuit. In March 2025, the court ruled in favor of the FDA and the wind-down for 503B compounding of tirzepatide finalized.
503A pharmacies can still compound tirzepatide for individual patients with valid prescriptions if the formula reflects clinical need (different dose, added ingredients with clinical justification, allergy to brand inactives). 503B mass production of tirzepatide copies ended.
Which Is Safer Based on the Data?
Mounjaro carries tirzepatide’s standard safety profile: GI side effects (nausea, diarrhea, vomiting in 18% to 26% across SURPASS), pancreatitis risk, gallbladder events, and a boxed warning for thyroid C-cell tumors based on rodent studies. Long-term safety data comes from SURPASS and SURMOUNT, totaling tens of thousands of patient-years.
Compounded tirzepatide inherits the molecule’s safety profile if the pharmacy produces accurate, sterile, correctly-dosed product. Added risks include dosing errors, salt form differences, unverified added ingredients, and sterility failures. The FDA’s adverse event reports show clusters of overdose events traced to compounded tirzepatide vials where patients miscounted units on U-100 syringes.
A 503B outsourcing facility with FDA inspection records is closer to brand safety than a small 503A pharmacy with no third-party testing.
Who Should Choose Which?
Diabetic patients with insurance coverage for Mounjaro typically come out ahead on brand: covered cost, autoinjector accuracy, FDA-approved labeling. Obesity patients comparing Zepbound to compounded tirzepatide have a tighter call because Lilly’s direct-pay vials are competitive on price.
Cash patients without coverage often choose compounded for the 30% to 60% price advantage. The choice should hinge less on price and more on which pharmacy ships the drug, which legal lane they use (503A vs 503B), and whether they publish testing data. TrimRx’s free assessment quiz walks through these factors to match patients to the right pathway.
Bottom line: Eli Lilly launched a direct-cash program for Mounjaro/Zepbound at lower prices to compete
FAQ
Is Compounded Tirzepatide the Same as Mounjaro?
The active drug is the same molecule. The product is not. Mounjaro is an FDA-approved branded autoinjector; compounded tirzepatide is a pharmacy-prepared vial without FDA approval, sometimes with added B12 or B6.
Can Compounded Tirzepatide Produce the Same Weight Loss as Mounjaro?
If the dose and molecule match, yes, based on SURMOUNT-1 (Jastreboff et al. 2022 NEJM) data showing 20.9% weight loss at 15 mg over 72 weeks. Real-world outcomes hinge on pharmacy potency accuracy.
Is Compounded Tirzepatide Legal in 2026?
Yes, under 503A for individual prescriptions with genuine clinical need. The 503B mass-compounding pathway closed when the FDA’s shortage decision held up in court in March 2025.
Why Is Mounjaro So Much More Expensive?
Mounjaro’s $1,069 list price reflects R&D recovery, FDA approval costs, autoinjector manufacturing, and PBM rebates. Eli Lilly’s LillyDirect program for Zepbound at $349 to $499 narrowed the gap with compounded prices.
Does Insurance Cover Compounded Tirzepatide?
Almost never. Commercial insurance, Medicare, and Medicaid don’t reimburse compounded GLP-1 or GIP/GLP-1 products. Patients pay cash.
Can I Switch From Mounjaro to Compounded Tirzepatide?
Yes, with provider supervision. Most protocols match your current Mounjaro dose in mg per week. Side effects shouldn’t change if dose is matched and pharmacy potency is accurate.
How Do I Verify a Compounded Tirzepatide Pharmacy Is Legitimate?
Ask whether they are 503A or 503B, whether they publish batch potency and sterility testing, what state board they’re licensed under, and whether they use tirzepatide base or a salt form. Reputable pharmacies answer all four without pushback.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
Tirzepatide for Men: How Results Differ From Women
The clinical trials for tirzepatide included both men and women, and the headline results, average weight loss of around 20 percent of body weight…
Tirzepatide for Women Over 50: Menopause, Metabolism, and What to Expect
Women over 50 who start tirzepatide are working with a set of biological variables that don’t exist in younger patients, and understanding those variables…
Regaining Weight After Stopping Tirzepatide: What to Expect
Weight regain after stopping tirzepatide is one of the most searched and least clearly answered questions in the GLP-1 space. Patients want to know…
